Andrew Weiss News
-
European and U.S. regulators are reviewing Novartis AG’s Gilenya pill for multiple sclerosis after reports of 11 deaths among patients who took the drug. The shares fell the most in more than five months.
-
Malcolm has $30 billion, a passion for steaks, and a plan to buy 3 billion steaks for $10 each on his next birthday.
-
Novartis AG’s kidney-cancer drug Afinitor also prevented breast cancer from worsening in a study that the Swiss drugmaker plans to use in applying for regulatory approval.
-
Roche Holding AG agreed to buy Anadys Pharmaceuticals Inc. for about $230 million to build its portfolio of experimental drugs for hepatitis C, a market that may be worth as much as $15 billion annually by 2019.
-
Roche Holding AG’s failure to persuade a U.S. panel to back Avastin in breast cancer is the third such loss for the Swiss drugmaker as it looks for new ways to expand sales of the world’s top-selling cancer medicine.
-
Novartis AG said that an experimental antibody relieved pain and stopped new attacks of gout better than a steroid injection in two advanced studies.
-
Roche Holding AG delayed development of the experimental diabetes drug taspoglutide by at least 12 to 18 months after more people than expected suffered from side effects such as skin reactions and digestive symptoms.
-
Novartis AG indicated Alcon Inc. shareholders should take another look at its $11.5 billion buyout offer now that an increase in the Swiss drugmaker’s share price and a rally in the franc have lifted the value of the bid.
-
Novartis AG asked European Union regulators to approve the Prexige pain pill that was pulled off the market four years ago, as the company seeks to revive a drug that once had the potential for $1 billion in annual sales.
-
Novartis AG will pay out-of-pocket costs for non-Medicare patients who use the company’s multiple sclerosis pill Gilenya when the drug, to be priced at $4,000 a month, goes on sale in the U.S. this week.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page